

| Market Applicability | | | | | | | |
|----------------------|----|----|----|----|----|----|----|
| Market | DC | GA | KY | MD | NJ | NY | WA |
| Applicable | X | X | X | X | X | X | X |

Gleevec (imatinib)

| Override(s) | Approval Duration |
|---------------------------------------|-------------------|
| Prior Authorization Quantity Limit | 1 year |

| Medications | Quantity Limit |
|--------------------|----------------------------------|
| Gleevec (imatinib) | May be subject to quantity limit |

APPROVAL CRITERIA

Requests for Gleevec (imatinib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML); **OR**
 - B. Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); **OR**
 - C. Gastrointestinal stromal tumors (GIST) (NCCN 1, 2A); **OR**
 - D. Dermatofibrosarcoma protuberans tumors; **OR**
 - E. Hypereosinophilic syndrome(HES) and/or chronic eosinophilic leukemia (CEL); **OR**
 - F. Aggressive systemic mastocytosis in those without D816V c-Kit mutation (results are confirmed); **OR**
 - G. Myelodysplastic-Myeloproliferative disorders associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements; **OR**
 - H. Desmoid tumors (NCCN); **OR**
 - I. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT) (NCCN 2A); **OR**
 - J. C-KIT mutated Melanoma (NCCN 2A); **OR**
 - K. Philadelphia chromosome positive lymphoblastic lymphoma (NCCN 2A); **OR**

| Market Applicability | | | | | | | |
|----------------------|----|----|----|----|----|----|----|
| Market | DC | GA | KY | MD | NJ | NY | WA |
| Applicable | X | X | X | X | X | X | X |

L. AIDS-Related Kaposi Sarcoma (NCCN 2A); **OR**

M. Recurrent chordoma (NCCN 2A).

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 4/2018.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.